An overview of the recent trials of corticosteroids for severe community-acquired pneumonia.

Authors

Benjamin Edland, Grant W Waterer

Published in

Expert review of respiratory medicine. Jun 08, 2025. Epub Jun 08, 2025.

Abstract

The use of corticosteroids in the setting of community-acquired pneumonia (CAP) remains controversial.
Here we review the evidence for and against corticosteroids in the setting of CAP with a particular focus on three recent randomized, placebo-controlled trials that have disparate results but significantly advance our knowledge in the field.
Current published data does not support widespread use of corticosteroids in CAP with evidence this is more likely to cause harm than benefit. The use of hydrocortisone in a limited number of patients with respiratory failure of less than 24 hours duration and a serum c-reactive protein >200 mg/L may be supportable if a high dependency setting is available to address hyperglycemia. Disparate results and polarized positions amongst experts in the field will only be resolved by studies with tighter entry criteria, better definition of target groups, consideration of the infecting pathogen and therapeutic window for benefit.

PMID:
40483569
Bibliographic data and abstract were imported from PubMed on 08 Jun 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.